Access cutting-edge psoriatic arthritis treatment through this clinical trial at a research site in New York. Study-provided care at no cost to qualified participants.
Access psoriatic arthritis specialists in New York at no cost
This study follows strict safety protocols and ethical guidelines
All study-related psoriatic arthritis treatment provided free
The trial is an open-label randomized study that will examine whether switching to a selective IL23 inhibitor (guselkumab) is more effective than switching to a second TNFi (golimumab) among patients with PsA who have an inadequate response to a TNFi.
Sponsor: University of Pennsylvania
Check if you qualify for this psoriatic arthritis clinical trial in New York, NY
If you're searching for psoriatic arthritis treatment options in New York, NY, this clinical trial may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.
Our New York research site is actively enrolling participants for this clinical trial. You'll receive care from experienced psoriatic arthritis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.